Skip to main content
. 2021 Aug 12;7(2):e001621. doi: 10.1136/rmdopen-2021-001621

Figure 6.

Figure 6

Change in mTSS from baseline at (A) week 24 and (B) week 52. *Nominal p<0.05, **nominal p<0.01. FIL, filgotinib; LS, least squares; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate.